Literature DB >> 9873762

Prophylactic treatment in Sweden--overtreatment or optimal model?

R C Ljung1.   

Abstract

At the haemophilia centre in Malmö, Sweden, regular prophylactic treatment is begun at 1-1 1/2 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level > 1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the future. Were continuous infusion, using a recombinate concentrate with a prolonged half-life, technically feasible and socially acceptable to the child, we would probably have attained the optimal model of prophylactic treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9873762     DOI: 10.1046/j.1365-2516.1998.440409.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.

Authors:  Jennifer A Dumont; Tongyao Liu; Susan C Low; Xin Zhang; George Kamphaus; Paul Sakorafas; Cara Fraley; Douglas Drager; Thomas Reidy; Justin McCue; Helen W G Franck; Elizabeth P Merricks; Timothy C Nichols; Alan J Bitonti; Glenn F Pierce; Haiyan Jiang
Journal:  Blood       Date:  2012-01-13       Impact factor: 22.113

2.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Authors:  Jerry S Powell; Neil C Josephson; Doris Quon; Margaret V Ragni; Gregory Cheng; Ella Li; Haiyan Jiang; Lian Li; Jennifer A Dumont; Jaya Goyal; Xin Zhang; Jurg Sommer; Justin McCue; Margaret Barbetti; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

3.  Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.

Authors:  Alexander H Miners; Caroline A Sabin; Keith H Tolley; Christine A Lee
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Persons with Haemophilia in Sweden- Experiences and Strategies in Everyday Life. A Single Centre Study.

Authors:  Elisabeth Brodin; Katharina S Sunnerhagen; Fariba Baghaei; Marie Törnbom
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

5.  A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.

Authors:  Yang Buyue; Tongyao Liu; John D Kulman; Garabet G Toby; George D Kamphaus; Susannah Patarroyo-White; Qi Lu; Thomas J Reidy; Baisong Mei; Haiyan Jiang; Glenn F Pierce; Jurg M Sommer; Robert T Peters
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

6.  Hemophilia prophylaxis adherence and bleeding using a tailored, frequency-escalated approach: The Canadian Hemophilia Primary Prophylaxis Study.

Authors:  Saunya Dover; Victor S Blanchette; Darius Wrathall; Eleanor Pullenayegum; Daniel Kazandjian; Byron Song; Sue Ann Hawes; Stéphanie Cloutier; Geroges E Rivard; Robert J Klaassen; Elizabeth Paradis; Nicole Laferriere; Ann Marie Stain; Anthony K Chan; Sara J Israels; Roona Sinha; MacGregor Steele; John K M Wu; Brian M Feldman
Journal:  Res Pract Thromb Haemost       Date:  2020-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.